RecruitingPHASE1, PHASE2NCT05932199

Neoadjuvant Durvalumab and Tremelimumab With and Without Chemotherapy for Mesothelioma

Studying Pleural mesothelioma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Baylor College of Medicine
Principal Investigator
Robert Ripley, MD
Baylor College of Medicine
Intervention
Durvalumab / tremelimumab(drug)
Enrollment
52 target
Eligibility
18 years · All sexes
Timeline
20242028

Study locations (2)

Collaborators

Duke Cancer Institute

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05932199 on ClinicalTrials.gov

Other trials for Pleural mesothelioma

Additional recruiting or active studies for the same condition.

See all trials for Pleural mesothelioma

← Back to all trials